Effect of HCV treatment response on insulin resistance: A systematic review and meta‑analysis Corrigendum in /10.3892/etm.2019.8334

Hu,Jing‑Hong; Chang,Ming‑Ling; Liu,Nai‑Jen; Yeh,Chau‑Ting; Huang,Tung‑Jung

doi:10.3892/etm.2019.7995

Effect of HCV treatment response on insulin resistance: A systematic review and meta‑analysis

Corrigendum in: /10.3892/etm.2019.8334

Authors:
- Jing‑Hong Hu
- Ming‑Ling Chang
- Nai‑Jen Liu
- Chau‑Ting Yeh
- Tung‑Jung Huang
View Affiliations

Affiliations: Division of Gastroenterology and Hepatology, Department of Internal Medicine, Chang Gung Memorial Hospital, Yunlin 63862, Taiwan, R.O.C., Department of Gastroenterology and Hepatology, Liver Research Center, Chang Gung Memorial Hospital, Linkou 33305, Taiwan, R.O.C., Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou 33305, Taiwan, R.O.C., Division of Thoracic Medicine, Department of Internal Medicine and Department of Medicine, Chang Gung Memorial Hospital, Yunlin 63862, Taiwan, R.O.C.
Published online on: September 11, 2019 https://doi.org/10.3892/etm.2019.7995
Pages: 3568-3578
Copyright: © Hu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Sustained virological response (SVR) in hepatitis C virus (HCV) patients treated with pegylated interferon α‑2a and ribavirin is associated with reduced insulin resistance (IR), measured as a reduction of homeostasis model assessment (HOMA) scores after 24 weeks of therapy, and reduced fasting serum insulin and serum glucose levels. The present meta‑analysis aimed to evaluate the effect of HCV treatment response on IR in HCV patients who achieved SVR and those who did not (non‑SVR) after receiving interferon (IFN)‑based therapy. The PubMed, Cochrane and Embase databases were searched using combinations of the following search terms: ‘HCV’, ‘hepatitis C’, ‘interferon’, ‘antiviral’, ‘treatment response’ and ‘insulin resistance’. The incidence of IR, HOMA‑IR and HOMA‑β, as well as fasting glucose and fasting insulin levels, were summarized in terms of basal values and values after the end of treatment for each study. A total of 8 studies were included in the final analysis. There was no significant difference in the reduction in IR between the SVR and non‑SVR groups (odds ratio, 0.995; 95% CI=0.613‑1.616; P=0.984). However, the SVR group had a significantly higher mean reduction in HOMA‑IR (difference in means=‑0.485; 95%CI=‑0.713 to ‑0.256; P<0.001) and HOMA‑β (difference in means=‑15.448; 95%CI=‑23.326 to ‑7.570; P<0.001) compared to the non‑SVR group. In conclusion, HCV patients who achieved SVR after IFN‑based therapy exhibited improvement in HOMA‑IR and HOMA‑β. The present results suggest that clinical management of IR and serum glucose levels may be an important way to impact the therapeutic response in HCV patients.

View Figures

View References

1	Lavanchy D: The global burden of Hepatitis C. Liver Int. 29 (Suppl 1):S74–S81. 2009. View Article : Google Scholar
2	Axley P, Ahmed Z, Ravi S and Singal AK: Hepatitis C virus and hepatocellular carcinoma: A narrative review. J Clin Transl Hepatol. 6:79–84. 2018.PubMed/NCBI
3	Pawlotsky JM: New Hepatitis C therapies: The toolbox, strategies, and challenges. Gastroenterology. 146:1176–1192. 2014. View Article : Google Scholar : PubMed/NCBI
4	Crouchet E, Wrensch F, Schuster C, Zeisel MB and Baumert TF: Host-targeting therapies for Hepatitis C virus infection: Current developments and future applications. Therap Adv Gastroenterol. 11:17562848187594832018. View Article : Google Scholar : PubMed/NCBI
5	Averhoff FM, Glass N and Holtzman D: Global burden of Hepatitis C: Considerations for healthcare providers in the United States. Clin Infect Dis. 55 (Suppl 1):S10–S15. 2012. View Article : Google Scholar : PubMed/NCBI
6	Dhingra A, Kapoor S and Alqahtani SA: Recent advances in the treatment of Hepatitis C. Discov Med. 18:203–208. 2014.PubMed/NCBI
7	Zignego AL, Ferri C, Pileri SA, Caini P and Bianchi FB; Italian Association of the study of liver commission on Extrahepatic manifestations of HCV infection, : Extrahepatic manifestations of Hepatitis C Virus infection: A general overview and guidelines for a clinical approach. Dig Liver Dis. 39:2–17. 2007. View Article : Google Scholar : PubMed/NCBI
8	Cacoub P, Gragnani L, Comarmond C and Zignego AL: Extrahepatic manifestations of chronic Hepatitis C virus infection. Dig Liver Dis. 46 (Suppl 5):S165–S173. 2014. View Article : Google Scholar : PubMed/NCBI
9	White DL, Ratziu V and El-Serag HB: Hepatitis C infection and risk of diabetes: A systematic review and meta-analysis. J Hepatol. 49:831–844. 2008. View Article : Google Scholar : PubMed/NCBI
10	Nadolnik K, Skrypnik D, Skrypnik K and Bogdański P: Diabetic nephropathy in the elderly-clinical practice. Rocz Panstw Zakl Hig. 69:327–334. 2018. View Article : Google Scholar : PubMed/NCBI
11	Moucari R, Asselah T, Cazals-Hatem D, Voitot H, Boyer N, Ripault MP, Sobesky R, Martinot-Peignoux M, Maylin S, Nicolas-Chanoine MH, et al: Insulin resistance in chronic Hepatitis C: Association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology. 134:416–423. 2008. View Article : Google Scholar : PubMed/NCBI
12	Wang CS, Wang ST, Yao WJ, Chang TT and Chou P: Hepatitis C virus infection and the development of type 2 diabetes in a community-based longitudinal study. Am J Epidemiol. 166:196–203. 2007. View Article : Google Scholar : PubMed/NCBI
13	Kralj D, Virović Jukić L, Stojsavljević S, Duvnjak M, Smolić M and Čurčić IB: Hepatitis C virus, insulin resistance, and steatosis. J Clin Transl Hepatol. 4:66–75. 2016. View Article : Google Scholar : PubMed/NCBI
14	El-Zayadi AR and Anis M: Hepatitis C virus induced insulin resistance impairs response to anti viral therapy. World J Gastroenterol. 18:212–224. 2012. View Article : Google Scholar : PubMed/NCBI
15	Petta S, Cammà C, Di Marco V, Alessi N, Cabibi D, Caldarella R, Licata A, Massenti F, Tarantino G, Marchesini G and Craxì A: Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection. Am J Gastroenterol. 103:1136–1144. 2008. View Article : Google Scholar : PubMed/NCBI
16	Deltenre P, Louvet A, Lemoine M, Mourad A, Fartoux L, Moreno C, Henrion J, Mathurin P and Serfaty L: Impact of insulin resistance on sustained response in HCV patients treated with pegylated interferon and ribavirin: A meta-analysis. J Hepatol. 55:1187–1194. 2011. View Article : Google Scholar : PubMed/NCBI
17	Guo X, Jin M, Yang M, Liu K and Li JW: Type 2 diabetes mellitus and the risk of hepatitis C virus infection: A systematic review. Sci Rep. 3:29812013. View Article : Google Scholar : PubMed/NCBI
18	Sheikh MY, Choi J, Qadri I, Friedman JE and Sanyal AJ: Hepatitis C virus infection: Molecular pathways to metabolic syndrome. Hepatology. 47:2127–2133. 2008. View Article : Google Scholar : PubMed/NCBI
19	Aghemo A, Prati GM, Rumi MG, Soffredini R, D'Ambrosio R, Orsi E, De Nicola S, Degasperi E, Grancini V and Colombo M: Sustained virological response prevents the development of insulin resistance in patients with chronic hepatitis C. Hepatology. 56:1681–1687. 2012. View Article : Google Scholar : PubMed/NCBI
20	Kawaguchi T, Ide T, Taniguchi E, Hirano E, Itou M, Sumie S, Nagao Y, Yanagimoto C, Hanada S, Koga H and Sata M: Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2. Am J Gastroenterol. 102:570–576. 2007. View Article : Google Scholar : PubMed/NCBI
21	Kawaguchi Y and Mizuta T: Interaction between hepatitis C virus and metabolic factors. World J Gastroenterol. 20:2888–2901. 2014. View Article : Google Scholar : PubMed/NCBI
22	Kim HJ, Park JH, Park DI, Cho YK, Sohn CI, Jeon WK and Kim BI: Clearance of HCV by combination therapy of pegylated interferon alpha-2a and ribavirin improves insulin resistance. Gut Liver. 3:108–115. 2009. View Article : Google Scholar : PubMed/NCBI
23	Delgado-Borrego A, Jordan SH, Negre B, Healey D, Lin W, Kamegaya Y, Christofi M, Ludwig DA, Lok AS and Chung RT; Halt-C Trial Group, : Reduction of insulin resistance with effective clearance of hepatitis C infection: Results from the HALT-C trial. Clin Gastroenterol Hepatol. 8:458–462. 2010. View Article : Google Scholar : PubMed/NCBI
24	Eslam M, Aparcero R, Kawaguchi T, Del Campo JA, Sata M, Khattab MA and Romero-Gomez M: Meta-analysis: Insulin resistance and sustained virological response in hepatitis C. Aliment Pharmacol Ther. 34:297–305. 2011. View Article : Google Scholar : PubMed/NCBI
25	Thompson AJ, Patel K, Chuang WL, Lawitz EJ, Rodriguez-Torres M, Rustgi VK, Flisiak R, Pianko S, Diago M, Arora S, et al: Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3. Gut. 61:128–134. 2012. View Article : Google Scholar : PubMed/NCBI
26	Petta S, Cammà C, Di Marco V, Cabibi D, Ciminnisi S, Caldarella R, Licata A, Massenti MF, Marchesini G and Craxì A: Time course of insulin resistance during antiviral therapy in non-diabetic, non-cirrhotic patients with genotype 1 HCV infection. Antivir Ther. 14:631–639. 2009.PubMed/NCBI
27	Cacoub P, Desbois AC, Comarmond C and Saadoun D: Impact of sustained virological response on the extrahepatic manifestations of chronic hepatitis C: A meta-analysis. Gut. 67:2025–2034. 2018. View Article : Google Scholar : PubMed/NCBI
28	Ciancio A, Bosio R, Bo S, Pellegrini M, Sacco M, Vogliotti E, Fassio G, Bianco Mauthe Degerfeld AGF, Gallo M, Giordanino C, et al: Significant improvement of glycemic control in diabetic patients with HCV infection responding to direct-acting antiviral agents. J Med Virol. 90:320–327. 2018. View Article : Google Scholar : PubMed/NCBI
29	Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J and Moher D: The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. J Clin Epidemiol. 62:e1–e34. 2009. View Article : Google Scholar : PubMed/NCBI
30	Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, Carpenter J, Rucker G, Harbord RM, Schmid CH, et al: Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ. 343:d40022011. View Article : Google Scholar : PubMed/NCBI
31	Hayden JA, van der Windt DA, Cartwright JL, Côté P and Bombardier C: Assessing bias in studies of prognostic factors. Ann Intern Med. 158:280–286. 2013. View Article : Google Scholar : PubMed/NCBI
32	Jung HJ, Kim YS, Kim SG, Lee YN, Jeong SW, Jang JY, Lee SH, Kim HS and Kim BS: The impact of pegylated interferon and ribavirin combination treatment on lipid metabolism and insulin resistance in chronic hepatitis C patients. Clin Mol Hepatol. 20:38–46. 2014. View Article : Google Scholar : PubMed/NCBI
33	Chan CH, Hansen RD, Gilliver RS and Jones BE: Sustained virological response following chronic hepatitis C treatment is associated with improvement in insulin resistance. Intern Med J. 43:656–662. 2013. View Article : Google Scholar : PubMed/NCBI
34	Khattab MA, Eslam M, Shatat M, Abd-Aalhalim H, Mousa YI, Samir F, Aly H, Shaker O and Shaker Y: Changes in adipocytokines and insulin sensitivity during and after antiviral therapy for hepatitis C genotype 4. J Gastrointestin Liver Dis. 21:59–65. 2012.PubMed/NCBI
35	Kawaguchi Y, Mizuta T, Oza N, Takahashi H, Ario K, Yoshimura T, Eguchi Y, Ozaki I, Hisatomi A and Fujimoto K: Eradication of hepatitis C virus by interferon improves whole-body insulin resistance and hyperinsulinaemia in patients with chronic hepatitis C. Liver Int. 29:871–877. 2009. View Article : Google Scholar : PubMed/NCBI
36	Laurito MP and Parise ER: Association between insulin resistance and sustained virologic response in hepatitis C treatment, genotypes 1 versus 2 and 3: Systematic literature review and meta-analysis. Braz J Infect Dis. 17:555–563. 2013. View Article : Google Scholar : PubMed/NCBI
37	Fried MW, Jensen DM, Rodriguez-Torres M, Nyberg LM, Di Bisceglie AM, Morgan TR, Pockros PJ, Lin A, Cupelli L, Duff F, et al: Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: Randomized study of higher doses of peginterferon alpha-2a and ribavirin. Hepatology. 48:1033–1043. 2008. View Article : Google Scholar : PubMed/NCBI
38	Chang ML, Kuo CJ, Pao LH, Hsu CM and Chiu CT: The evolving relationship between adiponectin and insulin sensitivity in hepatitis C patients during viral clearance. Virulence. 8:1255–1264. 2017. View Article : Google Scholar : PubMed/NCBI
39	Chang ML: Metabolic alterations and hepatitis C: From bench to bedside. World J Gastroenterol. 22:1461–1476. 2016. View Article : Google Scholar : PubMed/NCBI
40	Miczke A, Suliburska J, Pupek-Musialik D, Ostrowska L, Jabłecka A, Krejpcio Z, Skrypnik D and Bogdański P: Effect of L-arginine supplementation on insulin resistance and serum adiponectin concentration in rats with fat diet. Int J Clin Exp Med. 8:10358–10366. 2015.PubMed/NCBI
41	Kujawska-Luczak M, Szulinska M, Skrypnik D, Musialik K, Swora-Cwynar E, Kregielska-Narozna M, Markuszewski L, Grzymislawska M and Bogdanski P: The influence of orlistat, metformin and diet on serum levels of insulin-like growth factor-1 in obese women with and without insulin resistance. J Physiol Pharmacol. 69:2018.